S-588410 is a subunit vaccine commercialized by Shionogi, with a leading Phase II program in Bladder Cancer. According to Globaldata, it is involved in 6 clinical trials, of which 4 were completed, 1 is ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of S-588410’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for S-588410 is expected to reach an annual total of $8 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
S-588410 is under development for the treatment of advanced or metastatic bladder cancer, non-small-cell lung cancer, refractory medulloblastoma, pediatric diffuse intrinsic pontine glioma, refractory osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma. It is administered subcutaneously as an emulsion. The therapeutic candidate is a mixed peptide-cocktail vaccine of S-288310 and S-488410 comprising of five human leukocyte antigens (HLA)-A 2402-restricted epitope peptides derived from oncoantigen. The drug candidate is a new molecular entity. It was under development for the treatment of esophageal squamous cell carcinoma.
Shionogi focuses on the research, development, manufacturing, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. It develops innovative products and services in collaboration with its partners. The company offers prescription drugs, over-the-counter (OTC) drugs, and diagnostic products for the therapeutic areas including metabolic disorders, pain/central nervous system (CNS), infectious diseases and cancer. It offers contract development and manufacturing facilities including all stages from drug development to commercial manufacturing. The company operates a network of subsidiaries, branches, sales offices manufacturing plants, and research laboratories across Japan, China, Taiwan; North America and Europe. Shionogi is headquartered in Osaka, Japan.
The company reported revenues of (Yen) JPY426,684 million for the fiscal year ended March 2023 (FY2023), an increase of 27.3% over FY2022. In FY2023, the company’s operating margin was 34.9%, compared to an operating margin of 32.9% in FY2022. In FY2023, the company recorded a net margin of 43.3%, compared to a net margin of 34.1% in FY2022. The company reported revenues of JPY121,230 million for the second quarter ended September 2023, an increase of 10.9% over the previous quarter.
For a complete picture of S-588410’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.